Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab 3 mg/kg vs 10 mg/kg in Advanced Melanoma
NCT01515189Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2012
- Primary completion
- Feb 2016
- Modality
- Monoclonal Antibodies
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial of ipilimumab in melanoma (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Overall Survival at 48 months. Started Feb 2012; status: completed.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01515189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01515189.